AIRLINK 61.99 Increased By ▲ 1.56 (2.58%)
BOP 5.37 Increased By ▲ 0.02 (0.37%)
CNERGY 4.57 Decreased By ▼ -0.03 (-0.65%)
DFML 15.85 Increased By ▲ 1.01 (6.81%)
DGKC 66.00 Increased By ▲ 1.20 (1.85%)
FCCL 17.20 Increased By ▲ 0.34 (2.02%)
FFBL 27.65 Increased By ▲ 2.90 (11.72%)
FFL 9.25 Increased By ▲ 0.19 (2.1%)
GGL 10.15 Increased By ▲ 0.19 (1.91%)
HBL 105.40 Increased By ▲ 1.19 (1.14%)
HUBC 122.64 Increased By ▲ 5.12 (4.36%)
HUMNL 6.50 Decreased By ▼ -0.04 (-0.61%)
KEL 4.56 Increased By ▲ 0.01 (0.22%)
KOSM 4.57 No Change ▼ 0.00 (0%)
MLCF 36.18 Increased By ▲ 0.77 (2.17%)
OGDC 122.90 Increased By ▲ 0.51 (0.42%)
PAEL 22.70 Increased By ▲ 0.79 (3.61%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.85 Decreased By ▼ -0.09 (-1.52%)
PPL 106.20 Decreased By ▼ -1.17 (-1.09%)
PRL 27.35 Increased By ▲ 0.84 (3.17%)
PTC 18.46 Increased By ▲ 2.36 (14.66%)
SEARL 53.19 Decreased By ▼ -0.44 (-0.82%)
SNGP 63.91 Increased By ▲ 2.71 (4.43%)
SSGC 10.79 Increased By ▲ 0.04 (0.37%)
TELE 9.41 Increased By ▲ 0.92 (10.84%)
TPLP 11.15 Increased By ▲ 0.57 (5.39%)
TRG 73.05 Increased By ▲ 3.14 (4.49%)
UNITY 23.85 Increased By ▲ 0.34 (1.45%)
WTL 1.31 Increased By ▲ 0.03 (2.34%)
BR100 6,954 Increased By 76.5 (1.11%)
BR30 22,839 Increased By 270.9 (1.2%)
KSE100 67,199 Increased By 651.3 (0.98%)
KSE30 22,128 Increased By 213.1 (0.97%)

PARIS: Giving a full dose of Moderna’s Covid-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections, the company said Monday.

The lab study measured the levels of Omicron-neutralising antibodies in blood samples from 40 people who had low levels of these antibodies before getting the booster.

The current recommendation is to give 100 micrograms of the Moderna jab as a first and second dose for protection from Covid-19, followed by a 50-microgram booster.

Antibodies were measured 29 days after booster participants got the third jabs, with half getting a 50 microgram dose and half getting 100 micrograms.

Moderna says preliminary data show antibody response to Omicron at the 50 microgram dose increased 37-fold — but when the dose was doubled, antibody levels increased 83-fold.

Moderna CEO Stephane Bancel called the results “reassuring”, adding that the company is continuing to develop an Omicron-specific jab.

The statement says clinical trials for a targeted vaccine are likely to begin in early 2022.

Experts urge caution when interpreting lab studies, saying real-world evidence is needed to determine protection against transmission and illness.

Last week a real-world study from South Africa showed two shots of the similar mRNA jab from Pfizer/BioNTech offered around 70 percent protection against severe disease caused by Omicron.

In an interview published Monday in French daily Le Monde, BioNTech CEO Ugur Sahin said that after a third injection the jab seemed to provide between 70 and 75 percent protection against any form of the illness.

He added that his company should be able to offer an Omicron-specific vaccine from March, pending approval from regulators.

Comments

Comments are closed.